FDA changes course on Sarepta's once-rejected muscular dystrophy drug
from STAT News
The Food and Drug Administration reversed its decision on a treatment for Duchenne muscular dystrophy from Sarepta Therapeutics, approving a previously rejected drug without explaining what the problem was in the first place. The therapy, called Vyondys 53, is approved to treat the roughly 8% of Duchenne patients whose disease results from a specific DNA error.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063